Skip to content
Therabene logo — Pioneering PROTAC Molecules for Cancer and Autoimmune Diseas...

Therabene

Pioneering PROTAC Molecules for Cancer and Autoimmune Disease Treatment with Collaborative Vision.

Founded 2020 Debt Financing Total: $50.00K Biotechnology

General Information

Company Name Therabene
Founded Year 2020
Industries Biotechnology
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Therabene. To contact Therabene, visit therabene.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Therabene compare?

A PDF of Therabene and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Therabene soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Therabene

Therabene is a biotechnology firm founded in 2020, specializing in the development of PROTAC molecules for addressing cancer and autoimmune diseases. Led by experienced executive Dr. Mario DiPaola, with a notable 25-year career in the biotechnology and pharmaceutical sectors, the company emphasizes collaborative efforts to advance its molecule development. Therabene's collaborations span across academic and clinical research institutions, pharmaceutical, biopharma, and biotech companies, with a focus on specific assets and disease areas. The company recently secured a $50.00K Debt Financing at 11 October 2022, indicating continued financial support for its pioneering work in the biotechnology industry.

Business keywords: PROTAC molecules, cancer treatment, autoimmune disease treatment, collaborative vision, Dr. Mario DiPaola, pharmaceutical industry, biopharmaceutical industry, biotech industry, academic research institutions, clinical research institutions, partnerships, disease-specific assets, biotech collaborations, specialized drug development

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $50.00K -
11 Oct 2022

Therabene Alternatives & Competitors

View All Alternatives
Therabene vs
Bioniz, LLC
Bioniz, LLC United States

Pioneering the future of autoimmune and cancer treatment with innovative small peptides and molecule...

Acquired
3 employees
Biotechnology, Health Care
Therabene vs
SFA Therapeutics
SFA Therapeutics United States

A New Paradigm in Drug Development

Convertible Note
9 employees
Biotechnology, Health Care
Therabene vs

Resolving disease without compromising host defense

Grant
4 employees
Biotechnology, Pharmaceutical

FAQ About Therabene

Pioneering PROTAC Molecules for Cancer and Autoimmune Disease Treatment with Collaborative Vision.
Therabene was founded in 2020.
Therabene operates in Biotechnology. Its work centres on PROTAC molecules, cancer treatment, autoimmune disease treatment and collaborative vision.
Therabene has completed 1 funding round, raising a total of $50.00K. The latest funding stage is Debt Financing.
Top alternatives and competitors to Therabene include Bioniz, LLC, SFA Therapeutics, Thetis Pharmaceuticals, MEDIBIOFARMA SL, Biond Biologics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Therabene and Bioniz, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Therabene, https://www.bouncewatch.com/company/therabene, updated 11 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout